SCHEMBL26268362

SCHEMBL26268362

C[C@H]1[C@H](F)[C@H](n2cnc3c(=O)[nH]c(N)nc32)O[C@@H]1CO

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.58
▸ HINT1 P49773 4/20 0.54
▸ STING1 Q86WV6 3/20 0.52
▸ NT5E P21589 1/20 0.52
▸ PDE2A O00408 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ ADORA2A P29274 1/20 0.50
▸ ADORA1 P30542 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ PDE4D Q08499 1/20 0.50
▸ PDE3A Q14432 1/20 0.50
▸ GSK3A P49840 2/20 0.49
▸ RPS6KA3 P51812 2/20 0.49
▸ MAPK14 Q16539 2/20 0.49
▸ PNP P00491 2/20 0.49
▸ TGM2 P21980 1/20 0.48
▸ FUT5 Q11128 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15070556 1.00 HPGD (0.58) HPGDHINT1STING1NT5EPDE2A
SCHEMBL16375317 0.91 HINT1 (0.55) HPGDHINT1STING1NT5EGSK3A
SCHEMBL26268365 0.91 HINT1 (0.55) HPGDHINT1STING1NT5EGSK3A
SCHEMBL19035716 0.90 HPGD (0.61) HPGDHINT1STING1NT5EADORA3
SCHEMBL1738416 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A
SCHEMBL26208536 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A
SCHEMBL16317882 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A
SCHEMBL1738418 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A
SCHEMBL1738417 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A
SCHEMBL12031280 0.89 HPGD (0.64) HPGDHINT1STING1NT5EPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 HPGD 3566/4885HINT1 358/4885STING1 923/4885
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 HPGD 3566/4885HINT1 358/4885STING1 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback